Point prevalence abstinence at longest · smokers with COPD
1 finding from 1 review
Prolonged abstinence at longest · smokers with COPD
Pharmacological treatment leads to higher prolonged abstinence at longest compared with placebo (high certainty).
5 findings from 1 review
RR 2.53 [1.83, 3.5]
4 studies · 1429 participants
High
RR 2.6 [1.29, 5.24]
1 study · 370 participants
High
RR 2.03 [1.26, 3.28]
2 studies · 503 participants
Moderate
Show 2 more findings
Health‐related quality of life · people with asthma
Vilanterol and fluticasone furoate showed no clear difference in health‐related quality of life compared with placebo (moderate certainty).
1 finding from 1 review
MD 0.3
2012 participants
Moderate
Asthma exacerbations · people with asthma
1 finding from 1 review
Serious adverse events · people with asthma
1 finding from 1 review
no estimate extracted
2013 participants
Very low
FEV1 · people with asthma
Vilanterol and fluticasone furoate showed no clear difference in FEV1 compared with placebo (moderate certainty).
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · people with asthma
Vilanterol and fluticasone furoate showed no clear difference in peak expiratory flow compared with placebo (moderate certainty).
1 finding from 1 review
MD 33.3
2012 participants
Moderate
Asthma symptoms · people with asthma
Vilanterol and fluticasone furoate showed no clear difference in asthma symptoms compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · people with asthma
1 finding from 1 review
no estimate extracted
8 participants
Moderate
Quality of life · children with asthma
1 finding from 1 review
no estimate extracted
28 participants
Low
Asthma symptoms · children with asthma
1 finding from 1 review
no estimate extracted
78 participants
Low
Serious adverse events · children with asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · children with acute asthma in the emergency department
MgSO4 may leads to lower hospital admissions compared with placebo (low certainty).
1 finding from 1 review
ED treatment duration (minutes) · children with acute asthma in the emergency department
1 finding from 1 review
Return to ED within 48 hours · children with acute asthma in the emergency department
MgSO4 showed no clear difference in return to ED within 48 hours compared with placebo (low certainty).
1 finding from 1 review
Length of hospital stay · children with acute asthma in the emergency department
1 finding from 1 review
Intervention not reported
Change in Exercise Capacity (6MWD) · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
1 finding from 1 review
Intervention not reported
Mortality · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
The intervention showed no clear difference in mortality (low certainty).
1 finding from 1 review
Intervention not reported
Improvement in WHO Functional Class · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
The intervention showed no clear difference in improvement in WHO Functional Class (low certainty).
1 finding from 1 review
Intervention not reported
Serious Adverse Events (Participants with one or more event) · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
It is very uncertain whether the intervention changes serious Adverse Events (Participants with one or more event) (very low certainty).
1 finding from 1 review